Empowered Funds LLC Makes New Investment in Keros Therapeutics, Inc. $KROS

Key Points

• Empowered Funds LLC acquired 142,151 shares of Keros Therapeutics during the second quarter, valued at about $1.52 million and representing roughly 0.72% of the company. Institutional investors collectively own 71.56% of KROS.
• Keros reported a quarterly loss of $1.45 per share, missing analyst expectations of a $1.34 loss, while analysts project a full-year loss of $5.27 per share. Shares recently opened at $11.11, near the lower end of their 52-week range.
• Analyst sentiment is mixed, with four Buy, four Hold and one Sell rating; the stock carries an overall “Hold” consensus and an average price target of $20.50, despite recent target-price reductions and insider selling to cover tax obligations.

Empowered Funds LLC purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 142,151 shares of the company's stock, valued at approximately $1,521,000. Empowered Funds LLC owned about 0.72% of Keros Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Keros Therapeutics in the 2nd quarter worth approximately $29,898,000. Vanguard Group Inc. raised its holdings in shares of Keros Therapeutics by 3.3% in the third quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company's stock worth $43,011,000 after buying an additional 87,129 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in shares of Keros Therapeutics by 26.6% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company's stock worth $15,645,000 after buying an additional 161,336 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company's stock valued at $7,547,000 after buying an additional 205,022 shares during the last quarter. Finally, Federated Hermes Inc. increased its holdings in shares of Keros Therapeutics by 27.3% in the fourth quarter. Federated Hermes Inc. now owns 654,724 shares of the company's stock valued at $13,330,000 after purchasing an additional 140,564 shares during the period. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $11.11 on Friday. The company has a market cap of $220.31 million, a price-to-earnings ratio of -3.00 and a beta of 1.01. The stock has a 50 day simple moving average of $10.80 and a 200-day simple moving average of $11.40. Keros Therapeutics, Inc. has a 1-year low of $9.69 and a 1-year high of $22.55.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Analysts anticipate that Keros Therapeutics, Inc. will post -5.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of research reports. Leerink Partners decreased their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating for the company in a research report on Tuesday, August 4th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Keros Therapeutics in a report on Tuesday, August 4th. Wall Street Zen upgraded shares of Keros Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Monday, August 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Finally, Zacks Research upgraded Keros Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 27th. Four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Keros Therapeutics currently has an average rating of "Hold" and a consensus target price of $20.50.

Insiders Place Their Bets

In related news, insider Lorena Raquel Lerner sold 3,568 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the sale, the insider directly owned 27,559 shares in the company, valued at approximately $283,582.11. The trade was a 11.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 5,893 shares of company stock valued at $60,507. Company insiders own 12.60% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source